Reference health
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
113/113 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
13 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 113 checked references that resolve
resolves10.3109/08830185.2010.483028
Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity?
resolves10.1159/000491752
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West
resolves10.1136/annrheumdis-2019-215882
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
resolves10.1136/rmdopen-2019-001035
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
resolves10.1016/j.vaccine.2018.01.061
Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)
resolves10.2217/IMT.15.74
Vaccination in Patients with Primary Immune Deficiency, Secondary Immune Deficiency and Autoimmunity with Immune Regulatory Abnormalities
resolves10.1093/cid/cit816
Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
resolves10.1186/1479-5876-12-77
Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
resolves10.1016/j.clim.2018.07.010
Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy
resolves10.1016/j.vaccine.2010.12.072
The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab
resolves10.1016/j.vaccine.2017.01.048
Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports
resolves10.1056/NEJMoa2026920
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
resolves10.1016/S0140-6736(20)32466-1
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
resolves10.1016/S0140-6736(20)32661-1
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
resolves10.1056/NEJMoa2101544
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
resolves10.1016/S0140-6736(20)31208-3
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
resolves10.1016/S0140-6736(20)31866-3
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
resolves10.1016/S0140-6736(21)00234-8
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
resolves10.1001/jamacardio.2021.2833
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
resolves10.1016/S1473-3099(20)30843-4
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
resolves10.2139/ssrn.3820545
Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial
resolves10.1016/S0140-6736(21)01429-X
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
resolves10.1056/NEJMoa2105385
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
resolves10.1001/jama.2021.7517
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
resolves10.1016/j.vaccine.2015.11.062
Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
resolves10.1080/22221751.2021.1902245
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
resolves10.1038/s41467-021-23173-1
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
resolves10.1016/S0140-6736(21)01115-6
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
resolves10.1016/S2213-2600(21)00357-X
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
resolves10.1101/2021.05.30.21257971
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
resolves10.1136/annrheumdis-2021-220231
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
resolves10.1136/annrheumdis-2021-220272
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
resolves10.1136/annrheumdis-2021-220461
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
resolves10.1002/ajh.26132
Thrombocytopenia following Pfizer and Moderna <scp>SARS‐CoV</scp>‐2 vaccination
resolves10.1016/S1473-3099(21)00070-0
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
resolves10.1038/s41467-021-21639-w
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
resolves10.1126/science.abg3055
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
resolves10.1056/NEJMoa2102214
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
resolves10.1126/science.abh2644
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
resolves10.1038/s41586-021-03412-7
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
resolves10.1038/s41586-021-03426-1
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
resolves10.1016/S0140-6736(21)01358-1
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
resolves10.1172/JCI149335
SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63
resolves10.1056/NEJMc2104974
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
resolves10.1056/NEJMoa2108891
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
resolves10.1001/jama.2021.7489
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
resolves10.1172/JCI150175
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients
resolves10.1056/NEJMc2108861
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
resolves10.1136/annrheumdis-2021-220834
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response
resolves10.1038/s41586-021-03696-9
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
resolves10.1172/JCI149150
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
resolves10.1099/vir.0.82839-0
Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen
resolves10.1016/j.vaccine.2016.02.063
Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
resolves10.1038/s41467-021-22958-8
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
resolves10.1056/NEJMoa2024671
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
resolves10.1038/s41586-020-2608-y
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
resolves10.1016/j.vaccine.2020.10.064
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
resolves10.20411/pai.v6i1.441
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
resolves10.1016/j.xcrm.2020.100126
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
resolves10.1056/NEJMoa2104983
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
resolves10.1001/jama.2021.7563
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
resolves10.1001/jama.2021.5782
SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women
resolves10.1056/NEJMoa2107456
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
resolves10.1136/annrheumdis-2021-220647
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
resolves10.1093/rheumatology/keab345
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
resolves10.1371/journal.pmed.1002685
Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study
resolves10.1016/j.revmed.2017.01.005
Lupus érythémateux systémique et lymphopénie : aspects cliniques et physiopathologiques
resolves10.1016/j.semarthrit.2015.05.009
Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact—A systematic literature review
resolves10.1016/j.jaci.2021.05.029
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
resolves10.1101/2021.06.24.21259130
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: everybody does their best
resolves10.1016/j.ccell.2021.06.002
Seroconversion rates following COVID-19 vaccination among patients with cancer
resolves10.1016/S1470-2045(21)00213-8
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
resolves10.3389/fimmu.2021.704773
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
resolves10.1136/annrheumdis-2020-219773
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
resolves10.1002/art.41877
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2
resolves10.1136/annrheumdis-2021-220604
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
resolves10.1136/annrheumdis-2021-220656
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
resolves10.1101/2021.05.11.21256917
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
resolves10.1136/annrheumdis-2021-220408
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
resolves10.1136/annrheumdis-2021-220756
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
resolves10.55563/clinexprheumatol/xcdary
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
resolves10.3346/jkms.2021.36.e95
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
resolves10.1101/2021.04.05.21254656
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
resolves10.2217/imt-2020-0095
Currently Available Intravenous Immunoglobulin Contains Antibodies Reacting Against Severe Acute Respiratory Syndrome Coronavirus 2 Antigens
resolves10.1136/annrheumdis-2020-218946
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
resolves10.1111/dth.14627
The risk for severe
<scp>COVID</scp>
19 in patients with autoimmune and/or inflammatory diseases: First wave lessons
resolves10.1080/1744666X.2021.1873767
Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic
resolves10.1016/j.jaci.2020.04.013
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
resolves10.1016/j.jaci.2020.09.010
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
resolves10.1016/j.jaci.2020.12.620
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
resolves10.1111/imj.15247
<scp>COVID</scp>‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
resolves10.3389/fimmu.2021.656362
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group
resolves10.1056/NEJMoa2107058
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
The 13 references without a DOI — listed, not checked
no DOI — not checkedInfluenza vaccines in immunosuppressed adults with cancer
no DOI — not checkedConsiglio Superiore di Sanità (2018). Guida Alle Controindicazioni Alle Vaccinazioni, Consiglio Superiore di Sanità. [5th ed.]. A Cura di Giovanni Gallo, Rosanna Mel, Elisa Ros e Antonietta Filia.
no DOI — not checkedCenters for Disease Control and Prevention, Infectious Disease Society of America, and American Society of Blood and Marrow Transplantation (2000). Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm. Rep., 49.
no DOI — not checked(2021, June 12). Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
no DOI — not checkedAleem, A., and Nadeem, A.J. (2021, July 18). Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) [Updated 18 July 2021], StatPearlas [Internet], Available online: https://WWW.ncbi.nlm.nih.gov/books/NBK570605.
no DOI — not checked(2021, July 03). Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_England.pdf.
no DOI — not checked(2021, July 03). Available online: https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/ 2021_01_11_Transmissibil-ity_and_severity_of_501Y_V2_in_SA.pdf.
no DOI — not checked(2021, July 03). Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975742/Variants_of_Concern_VOC_Technical_Briefing_8_England.pdf.
no DOI — not checkedECDC-European Center for Disease Control (2021, July 03). SARS-CoV-2 Variants of Concern as of 6 May 2021. Available online: https://www.ecdc.europa.eu/en/covid-19/variants-concern.
no DOI — not checkedmRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
no DOI — not checkedSquire, J., and Joshi, A. (2021). Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients. Ann. Allergy Asthma Immunol.
no DOI — not checkedAmerican College of Rheumatology (2021). COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Mus-culoskeletal Diseases. Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. This draft summary was ap-proved by the ACR Board of Directors on February 8, 2021, and updated on March 4, 2021. A full manuscript is pending journal peer review. Arthritis Rheumatol., 73, 1093–1107.
no DOI — not checkedPisani, G., Cristiano, K., Simeoni, M., Martina, A., Pati, I., Carocci, A., Gaggioli, A., Marino, F., Adriani, D., and Pupella, S. (2021). Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic. Blood Transfus.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3390/biomedicines9091163"><img src="https://citestamp.com/citestamped/10.3390/biomedicines9091163/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3390/biomedicines9091163)